Victoria's Secret Beats on Profits and Raises Guidance, So Why Are Investors Dumping the Stock
Shares plunged 16.3% to $71.00 in pre-market trading on September 3 after Victoria's Secret delivered a quarter that looked strong on paper but failed to clear the sky-high bar the market had set for a stock up nearly 300% in a year. The results expose a growing tension: the turnaround under CEO Hillary Super is real, but at these valuations, good is no longer good enough.
A Revenue Miss of Pennies Overshadows a Blockbuster Earnings Beat
Net sales hit $1.611 billion, up 10% year-over-year and near the high end of the company's own guidance range of $1.59–$1.615 billion. But the Street wanted more — consensus revenue expectations sat around $1.62 billion , and even a hairline miss matters when a stock trades at 34.5x trailing earnings — some 231% above its five-year median price-to-earnings ratio. Meanwhile, adjusted EPS of $0.95 blew past both the company's own $0.65–$0.75 guidance and the $0.78 Wall Street estimate , suggesting the profit engine is running hotter than the top line.
A $140 Million Tariff Refund Flatters the Headline Numbers
Reported operating income surged to $257 million from just $41 million a year ago, but the quarter included over $140 million in IEEPA tariff refunds — money the government returned after the company paid import duties. Strip that out, and adjusted operating income was $124 million, still more than double the prior year — but the gap between the GAAP and adjusted figures reminds investors that not all of the improvement is repeatable.
Raised Guidance Still Leaves the Growth-Rate Question Open
The company lifted fiscal 2026 full-year sales guidance to $7.10–$7.18 billion , a second consecutive raise after Q1's bump to $7.03–$7.13 billion. That signals management confidence, yet comparable sales growth decelerated from 13% in Q1 to 9% in Q2. For a stock that had priced in an accelerating comeback, the slowdown stings.
A 300% Rally Left No Room for Error
VSXY surged 290% over the past 52 weeks , fueled by brand revitalization and the impact of GLP-1 weight-loss drugs on consumer purchasing habits. With short interest still at roughly 13.8% of shares outstanding and insiders net sellers of $212 million over the past year , the stock was primed for a violent reaction to any disappointment. The move reflects a cleaner turnaround story, but it also leaves less room for execution missteps. Today's selloff is the market recalibrating expectations — not abandoning the thesis, but demanding proof the growth rate can keep pace with the price tag.